Print Page  |  Close Window

Investor Overview

Corporate Profile

Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to leverage our BioSymphony™ Platform to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company.

Latest News

April 17, 2018

Oncobiologics Appoints Randy Thurman to Board of Directorsmore >

March 27, 2018

Oncobiologics Appoints Dr. Joerg Windisch to Board of Directorsmore >

February 14, 2018

Oncobiologics Reports First Quarter Fiscal Year 2018 Resultsmore >

Upcoming Events

There are currently no events scheduled.